Comprehensive analytical testing requires a range of materials, including pharmacopeial and non-pharmacopeial impurities, degradation products, and synthetic intermediates, to support robust method validation and regulatory compliance. Accurate impurity profiling is necessary to identify and quantify process-related byproducts, such as deletion sequences or isomers, which can affect therapeutic performance. Furthermore, stable isotope labelled compounds are indispensable tools for high-precision quantification in complex bioanalytical workflows, including liquid chromatography-mass spectrometry. By relying on well-characterized standards, researchers can effectively monitor structural integrity and maintain strict quality control standards throughout the lifecycle of peptide-based drug development.
![Chemical structure of N-((2R,6S,9S,11R,12S,14aS,20S,23S,25aS)-20-((R)-3-Amino-1-hydroxypropyl)-12-((2-aminoethyl)amino)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11-dihydroxy-6-((R)-1-hydroxyethyl)-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-10,12-dimethyltetradecanamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2142583-72-8-N-2R6S9S11R12S14aS20S23S25aS-20-R-3-Amino-1-hydroxypropyl-12-2-aminoethylamino-23-1S2S-12-dihydroxy-2-4-hydroxyphenylethyl-211-dihydroxy-.png&w=3840&q=75)
